News | Proton Therapy | June 14, 2019

University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA

Streamlined quality assurance process will allow Netherlands center to treat more patients per day

University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA

June 14, 2019 – IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and clinically implemented a novel automated treatment log-based patient quality assurance (QA) approach for proton therapy. This enables them to reduce the time needed for the in-beam measurement-based conventional patient QA.

With this new approach, the center is now able to streamline and reduce the QA time per patient, extract more clinically relevant information from the QA data and establish continuous quality control of the treatment throughout the course. Furthermore, this will allow them to reduce the time to continue treatment course with adapted plans, when needed, and make a step towards supporting online adaptive workflows.

This new automated patient QA approach combines several open source projects: CAPTAIN, an automatic workflow manager using web-technology; a DICOM picture archiving and communication system (PACS) database (Orthanc) providing an interface with the treatment planning system (TPS); computation routines from open-REGGUI and others, developed at UMCG; and a Monte Carlo proton dose engine (MCsquare).

CAPTAIN, open-REGGUI and MCsquare are open-source research tools supported by the openPath initiative, which is aimed at researchers, medical physicists and clinicians to accelerate research. It is the first time that a center has applied the extensive internal QA validation of UMCG to use the open source software platform in the clinic.

Prof. Stefan Both, head of physics at UMCG, commented, “Thanks to the support of IBA and the OpenPath platform, we managed to develop and implement an automated patient QA process that will allow us to considerably reduce the time to perform patient QA operations from about 45 minutes to 5 minutes. This means we have today the capacity to treat [an] additional 1 to 2 fractions per day, shorten [by] two days the time from simulation to treatment delivery and explore adaptive proton therapy protocols to maximize the clinical potential of the proton treatment beam.”

For more information: www.iba-worldwide.com

Related Content

New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Canon Medical Receives FDA Clearance for AiCE Reconstruction Technology for CT
Technology | Computed Tomography (CT) | June 18, 2019
Canon Medical Systems USA Inc. has received 510(k) clearance on its new deep convolutional neural network (DCNN) image...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
Fujifilm Announces Nationwide Breast Health Campaign With Mobile Mammography Coach

At the center of the campaign, Fujifilm will be traveling around the U.S. with its "Aspire to Be Fearless" mobile mammography coach to provide educational opportunities for clinicians, raise awareness about the importance of screening and will be providing mammograms to the underserved population in key locations.

News | Mammography | June 14, 2019
Fujifilm Medical Systems U.S.A. Inc. announced a nationwide awareness campaign titled ‘Aspire to Be Fearless’ focused...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Civco Launches Envision Ultrasound Viral Barriers
Technology | Ultrasound Imaging | June 06, 2019
Civco Medical Solutions announced a new solution that removes gel from ultrasound procedures. Envision viral barriers...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing  synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of  the anatomy.

A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of the anatomy.

Feature | Radiation Oncology | May 29, 2019 | By Jeff Zagoudis